1-11 of 11
Perla Eleftheriou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Experience of Patients with Sickle Cell Disease Treated with Voxelotor: A Single Centre Experience at University College Hospital in London

Constantinos Loukari, Dreen Gul, May Low, Perla Eleftheriou
Journal: Blood
Blood (2024) 144 (Supplement 1): 5312.
https://doi.org/10.1182/blood-2024-205722
Published: 2024
Journal Articles

Trials in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase 1b CROSSWALK-a and Phase 2a CROSSWALK-c Trials - Crovalimab for the Treatment and Prevention of Vaso-Occlusive Episodes in Sickle Cell Disease

Marco Aurelio Salvino, Bulent Antmen, Frederick Chite Asirwa, Satheesh Chonat, Lucia De Franceschi, Perla Eleftheriou, Adlette Inati, Johnny Mahlangu, Erfan Nur, Salvador Payán-Pernía, Asad Charania, Diana Gradinaru, Allison Hsia, Yves Luder, Thomas Perretti, Sasha Srekovic, Pablo Bartolucci
Journal: Blood
Blood (2023) 142 (Supplement 1): 1158.
https://doi.org/10.1182/blood-2023-179858
Published: 2023
Journal Articles

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Biree Andemariam, Timothy Mant, Perla Eleftheriou, Sanne Lugthart, Lanetta Bronté-Hall, Filipa Barroso, Gershwin Blyden, James Mason, Constance M Barysauskas, Joseph Yen, Karen Tang, Rahul Ballal, Kenneth Attie
Journal: Blood
Blood (2021) 138 (Supplement 1): 2046.
https://doi.org/10.1182/blood-2021-149536
Published: 2021
Journal Articles

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Lanetta Bronte-Hall, MD MPH, MSPH, Biree Andemariam, MD, Blyden Gershwin, MD, Sanne Lugthart, MD PhD, Timothy Mant, MB, FFPM, FRCP, Jo Howard, MBBChir, MRCP, FRCPath, Henry Fok, MBBS, PhD, Perla Eleftheriou, FRCPath, MRCP, Robert Ward Hagar, MD, James Mason, DO, Rahul Ballal, PhD, Joelle Lufkin, MPH, Eleanor Lisbon, MD MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-140540
Published: 2020
Journal Articles

Evaluating the Volumetric Liver Fat Fraction in Patients Referred for Investigation of Hyperferritinemia

Aoife Dervin, MBBS, BSc, MRCP, Perla Eleftheriou, FRCPath, MRCP, Deepak Suri, MBBS FRCP, Sara Trompeter, MBChB BSc MRCPCH FRCPath MSc, Maciej W Garbowski, MD PhD, Tim St. Pierre, John B. Porter, MA MDFRCP FRCPath, Emma Drasar, MBBS MRCP FRCPath PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3539.
https://doi.org/10.1182/blood-2019-128122
Published: 2019
Journal Articles

Pregnancy Outcomes in Patients with Sickle Cell Syndromes Managed Antenatally with Exchange Transfusions: A Single Centre Analysis

Evangelia Vlachodimtropoulou Koumoutsea, MBBS, Hutachok Nuntouchaporn, BSc, Perla Eleftheriou, FRCPath, MRCP, Patrick O'Brien, John Porter, MA MDFRCP FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 3666.
https://doi.org/10.1182/blood-2018-99-113619
Published: 2018
Journal Articles

Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Simon Cheesman, Raakhee Shah, MPharm, Sara Trompeter, MD, Perla Eleftheriou, FRCPath, MRCP, Bernadette Hylton, RN, Maciej W Garbowski, MDPhD, John Porter, MA MDFRCP FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 1062.
https://doi.org/10.1182/blood-2018-99-119030
Published: 2018
Journal Articles

Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report

Laura Chebet Kirui, MRCP, FRCPath, Marie Scully, MD MRCP, FRCPath, Norma Mcqueen, Bsc, John Porter, MA MDFRCP FRCPath, Perla Eleftheriou, FRCPath, MRCP
Journal: Blood
Blood (2018) 132 (Supplement 1): 4922.
https://doi.org/10.1182/blood-2018-99-118396
Published: 2018
Journal Articles

Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox

Maciej Garbowski, Perla Eleftheriou, Dudley Pennell, Mark Tanner, John B Porter
Journal: Blood
Blood (2008) 112 (11): 116.
https://doi.org/10.1182/blood.V112.11.116.116
Published: 2008
Journal Articles

MRI Evidence of Cardiac Iron Accumulation in Myelodysplasia and Unusual Anaemias.

Julie Glanville, Perla Eleftheriou, John Porter
Journal: Blood
Blood (2006) 108 (11): 1553.
https://doi.org/10.1182/blood.V108.11.1553.1553
Published: 2006
Journal Articles

Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox).

John B. Porter, MD, Mark A. Tanner, MRCP, Dudley J. Pennell, MD, Perla Eleftheriou, MD
Journal: Blood
Blood (2005) 106 (11): 3600.
https://doi.org/10.1182/blood.V106.11.3600.3600
Published: 2005